Abstract:
The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a horse against African horse sickness virus, compositions comprising said vectors, methods of vaccination against African horse sickness virus, and kits for use with such methods and compositions.
Abstract:
The present invention relates to novel thioamide derivatives of formula (I) and formula (Ia): wherein, R 3 , R 4 , R 5 , R 6 , R 7 , P, Q, T, V, W, X, Y, Z, a, m and n are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.
Abstract:
The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals, in particular dogs, against influenza.
Abstract:
The present invention encompasses a flow-through dispersion device for the dispersion of cell aggregates, the device comprising a first or upstream inlet obstacle and a second or downstream outlet obstacle, each obstacle having at least one traversing hole wherein no two holes align. Between the two obstacles is a turbulence chamber, such that when a cell suspension is passed through the inlet holes, into the chamber and then exits the second obstacle, the turbulence within the chamber disrupts and disperses cell aggregates. The device optionally may have more than two obstacles and turbulence chambers and multiple units may be placed in series to increase the amount of turbulence and time applied to a volume of cells. The invention further encompasses methods of using the device to disperse cell aggregates, and methods of culturing cells that involve seeding cultures and maintaining dispersed individual cells.
Abstract:
The present invention provides vectors that contain and express in vivo Leishmania KMP11 or an epitope thereof that elicits an immune response in a dog against Leishmania, compositions comprising said vectors, methods of vaccination against Leishmania , and kits for use with such methods and compositions.
Abstract:
Aspects of the present invention also provide methods based on novel UCN3 nucleotide polymorphisms selected from the group consisting of AAFC03043460.1 :g.8272- 8281AATAATAAAT>GGAGC, g.8208OT, g.8265OT, g.8287T>C, g.8412A>G, g,8426T>A, C.8786OT, g.9074T>C, C.12609OT, c.l2621T>C, c.l2667T>G and C.12669OA, which may provide novel markers for marbling and/or subcutaneous fat. Additional aspects provide for novel methods which may comprise marker-assisted selection or marker-assisted management to improve marbling and/or subcutaneous fat depth in cattle.
Abstract:
The invention provides a novel method of vaccination of a pig against Mycoplasma hyopneumoniae by administering to a weaned piglet or a sow, a single dose of an effective amount of a Mycoplasma hyopneumoniae vaccine. The Mycoplasma hyopneumoniae vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine.
Abstract:
An energy absorbing container (100) including a shell formed of a plastic material, one or more energy absorbing components (108) for absorbing energy resulting from impact loads, the energy absorbing components securing a bottle (102) stored within the container to prevent movement of the bottle within the container, and an opening mechanism for opening the container and allowing the placement or removal of a bottle therefrom.
Abstract:
The present invention relates to improved inactivated feline calicivirus (FCV) vaccines. The invention also provides a process for producing stabilized inactivated FCV, and the use of such stabilized inactivated FCV, in the production of FCV immunogenic compositions. The invention further provides methods of inducing an immune response in an animal of the Felidae family, preferably a cat, using the immunogenic compositions according to the invention.
Abstract:
The invention relates to a stabilized premix feed or feed-like formulation that has an extended shelf life due to a decrease of the degradates of the active ingredient by controlling the amount of an already existing stabilizer in the formulation. The feed premix is used in the treatment or prophylaxis of parasites in mammals, in particular swine and horses. The invention further relates to a method to extend the shelf life of a stable premix feed or feed-like formulation for the treatment or prophylaxis of parasite infestation in swine and horses comprising controlling the amount of an already existing antioxidant or stabilizer in the formulation to decrease or to prevent the formation of acid/base catalyzed decomposition of the active ingredient.